This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Touloukian, C. E. Articles by Restifo, N. P. Search for Related Content PubMed PubMed Citation Articles by Touloukian, C. E. Articles by Restifo, N. P.

Mining the Melanosome for Tumor Vaccine Targets

P.polypeptide Is a Novel Tumor-associated Antigen

Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892

To identify novel, tumor-specific target antigens for vaccine development, we studied immune responses to P.polypeptide, an M_r 110,000 integral melanosomal membrane protein associated with the Prader-Willi syndrome. Together with expressed sequence tag (EST) and serial analyses of gene expression (SAGE) library analyses, reverse transcription-PCR and Northern blotting verified that P.polypeptide expression was limited to melanoma and melanocytes. A single dominant epitope corresponding to positions 427–435 (IMLCLIAAV) was identified using allele-specific epitope forecasting combined with work in HLA-A*0201/K^b transgenic mice. This epitope was then used to generate de novo human P.polypeptide-specific CD8⁺ T cells capable of recognizing P.polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P.polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines.

This article has been cited by other articles:

				K.-i. Yasumoto, H. Watabe, J. C. Valencia, T. Kushimoto, T. Kobayashi, E. Appella, and V. J. Hearing Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT J. Biol. Chem., July 2, 2004; 279(27): 28330 - 28338. [Abstract] [Full Text] [PDF]